Baxter International (BAX) Financials

Baxter International’s recent financials show a company that is still under pressure, but with some signs of operating stabilization in early 2026. Over the last four years, Baxter’s results have been heavily affected by discontinuations, restructuring, large non-cash charges, and major swings in cash flow. Revenue has been fairly resilient, but profitability has been volatile and balance sheet leverage remains elevated.

• Revenue held up in Q1 2026 at $2.70 billion, down only modestly from $2.97 billion in Q4 2025 and generally in line with the broader 2025 quarterly run rate.
• Operating cash flow rebounded to $213 million in Q1 2026, up from a weak $584 million in Q4 2025? actually on a quarterly basis it remained positive and improved meaningfully versus Q1 2025, when operating cash flow was negative $193 million.
• Gross margin improved sharply in Q1 2026: gross profit was $891 million on $2.70 billion of revenue, versus $577 million on $2.97 billion in Q4 2025.
• Operating losses narrowed dramatically from late 2025, with Q1 2026 operating income of $66 million compared with an operating loss of $729 million in Q4 2025.
• Cash and equivalents rose to $2.02 billion at March 31, 2026, up from $1.73 billion at Q3 2025 and $1.76 billion at year-end 2024.
• Share count has been relatively stable, with weighted average diluted shares around 513–515 million in the last several quarters.
• Capital spending remains moderate, with Q1 2026 capex of $137 million, similar to recent quarters.
• Balance sheet equity improved from late 2025, with total common equity rising to $6.04 billion in Q1 2026 from $7.24 billion in Q3 2025 and $6.96 billion at year-end 2024; however, it still sits below prior-year levels seen in 2023–2024.
• Bottom-line profitability is still weak: Q1 2026 ended with a net loss of $15 million and diluted EPS of $(0.03).
• Debt remains a major overhang, including $842 million of short-term debt and $8.62 billion of long-term debt in Q1 2026.
• Interest expense and other non-operating items continue to pressure earnings, with Q1 2026 pre-tax income at a loss of $6 million despite positive operating income.
• 2024 and 2025 were marked by large losses and volatility, including Q4 2025 net loss of $1.13 billion and Q4 2024 net loss of $510 million.
• Working capital has been choppy, with large swings in receivables, inventories, and accrued expenses across the last several quarters.
• Goodwill and intangible assets make up a large portion of assets, which can increase risk if future impairments are needed.

Longer-term trend: Baxter’s revenue has not collapsed, but earnings quality has been inconsistent. In 2023, the company benefited from very large discontinued-operations gains and special items, which made reported profit look stronger than the core business. In 2024, the story turned much worse, with significant losses and large operating charges. Through 2025, the core business showed periods of improvement, but quarterly results remained uneven. The latest quarter suggests the business may be stabilizing operationally, yet leverage and weak net earnings still limit the investment case.

Key takeaway for retail investors: Baxter looks like a turnaround story that is not fully healed. The good news is that operating cash flow and core operations improved in Q1 2026. The bad news is that the company is still carrying substantial debt and has not yet demonstrated consistent net profitability. Investors will likely want to see several more quarters of stable margins, positive earnings, and debt reduction before calling the recovery complete.